New biosensor developed by University of Osaka tracks rare lipid accumulation during cell stress

On July 2, 2026, researchers from the University of Osaka unveiled a groundbreaking biosensor that tracks the accumulation of a rare lipid, PI(3,5)P₂, in cellular membranes under stress conditions. This innovative technology aims to enhance our understanding of lipid behavior in biological processes and diseases.

Introducing the CLiB Assay

The newly introduced cell surface liposome binding (CLiB) assay represents a significant advancement in lipid detection. Utilizing yeast cells and fluorescence readouts, this high-throughput method allows researchers to test thousands of protein variants for their ability to bind lipids simultaneously. Lead author Taki Nishimura emphasized the assay's potential, stating, "Until now, researchers have lacked a systematic way to develop specific lipid biosensors, which has been a major bottleneck in studying the roles of lipids in biology and disease."

The CLiB assay not only streamlines the process of developing lipid biosensors but also enables the tracking of previously elusive lipids in living cells. This enhanced sensitivity and selectivity mark a pivotal shift in lipid research.

Unexpected Findings Under Stress

Using the CLiB assay, the team successfully refined a sensor to create a new probe, PX-SnxA GV, capable of detecting PI(3,5)P₂. This lipid usually exists in trace amounts, making it challenging to study. However, under stress conditions, such as increased salt levels, the probe revealed that PI(3,5)P₂ accumulates in distinct regions of the cell membrane.

Additionally, in mammalian cells undergoing microautophagy—a process where lysosomes engulf damaged components—PI(3,5)P₂ concentrations were found at sites where the membrane begins to fold inward. This discovery enhances our understanding of how cells respond to stress and manage internal resources.

Implications for Disease Research

The implications of the CLiB assay extend beyond basic research. Many diseases, including cancer, diabetes, and neurodegenerative disorders, involve disruptions in lipid metabolism and cell membrane integrity. By providing a method to visualize and quantify lipid behavior, this new technology could open doors to novel therapeutic strategies.

Nishimura noted, "With these probes, we can now see when and where lipids appear inside cells. These advances will deepen our understanding of membrane lipid environments and how they influence a wide range of diseases." The CLiB assay thus holds promise not only for academic research but also for practical applications in medical research and AI-driven drug development.

• New biosensor tracks PI(3,5)P₂ accumulation
• Developed by University of Osaka researchers
• Uses high-throughput screening method
• Potential applications in studying diseases like cancer and diabetes

This innovative approach to lipid research represents a significant leap forward, potentially accelerating discoveries in cell biology and beyond.